Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Ivkovic-Kapic, Tatjana (56246924300)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study
    (2019)
    Ivkovic-Kapic, Tatjana (56246924300)
    ;
    Knezevic-Usaj, Slavica (6603358705)
    ;
    Moldvaji, Eva (57209413296)
    ;
    Jovanic, Irena (55623723900)
    ;
    Milovanovic, Zorka (25228841900)
    ;
    Milentijevic, Maja (7801549028)
    ;
    Tatic, Svetislav (6701763955)
    ;
    Mitrovic, Slobodanka (36017336100)
    ;
    Stojiljkovic, Miodrag (25959427400)
    ;
    Cvetanovic, Ana (55886180500)
    Purpose: The purpose of this study was to assess the immunohistochemistry and chromogenic in situ hybridization (CISH) inter-laboratory consensus between national pathology laboratories in Serbia. Methods: This study was conducted between 2013 and 2016. In 2013, HER2 results were evaluated using two sets of four different breast cancer specimens in five laboratories. A total of 20 immunohistochemistry and 20 CISH cases were tested. In 2014, there were 6 testing rounds, and a total of 24 specimens were analyzed, whereas in 2015 and 2016, seven testing rounds were conducted, with four additional cases (i.e. a total of 28 specimens). In 2014, 2015 and 2016, all institutions performed immunohistochemical analysis only. Results: We found discrepancies in HER2 immunohistochemical (IHC) results in all four surveys. IHC testing resulted in diagnostic discordance between participating centers in two (2/17) cases in 2013, two (2/24) in 2014, four (4/27) cases in 2015 and three cases (3/27) in 2016. The overall agreement among the centers was 79%, 85.5%, 83.5% and 89.4%, respectively. For CISH analyses, the results for 16 (84.2%) of 19 samples were consistent for all participants. Three results were found to be discordant, indicating a misdiagnosis rate of 15.8%. In all the discrepant cases, interinstitutional discordances were related to technical and evaluation issues. Conclusions: Our study highlights the difficulty encountered during HER2 testing using immunohistochemistry and CISH. This also emphasizes the need for rigorous quality control procedures for specimen preparation and analysis. © 2019 Zerbinis Publications. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study
    (2019)
    Ivkovic-Kapic, Tatjana (56246924300)
    ;
    Knezevic-Usaj, Slavica (6603358705)
    ;
    Moldvaji, Eva (57209413296)
    ;
    Jovanic, Irena (55623723900)
    ;
    Milovanovic, Zorka (25228841900)
    ;
    Milentijevic, Maja (7801549028)
    ;
    Tatic, Svetislav (6701763955)
    ;
    Mitrovic, Slobodanka (36017336100)
    ;
    Stojiljkovic, Miodrag (25959427400)
    ;
    Cvetanovic, Ana (55886180500)
    Purpose: The purpose of this study was to assess the immunohistochemistry and chromogenic in situ hybridization (CISH) inter-laboratory consensus between national pathology laboratories in Serbia. Methods: This study was conducted between 2013 and 2016. In 2013, HER2 results were evaluated using two sets of four different breast cancer specimens in five laboratories. A total of 20 immunohistochemistry and 20 CISH cases were tested. In 2014, there were 6 testing rounds, and a total of 24 specimens were analyzed, whereas in 2015 and 2016, seven testing rounds were conducted, with four additional cases (i.e. a total of 28 specimens). In 2014, 2015 and 2016, all institutions performed immunohistochemical analysis only. Results: We found discrepancies in HER2 immunohistochemical (IHC) results in all four surveys. IHC testing resulted in diagnostic discordance between participating centers in two (2/17) cases in 2013, two (2/24) in 2014, four (4/27) cases in 2015 and three cases (3/27) in 2016. The overall agreement among the centers was 79%, 85.5%, 83.5% and 89.4%, respectively. For CISH analyses, the results for 16 (84.2%) of 19 samples were consistent for all participants. Three results were found to be discordant, indicating a misdiagnosis rate of 15.8%. In all the discrepant cases, interinstitutional discordances were related to technical and evaluation issues. Conclusions: Our study highlights the difficulty encountered during HER2 testing using immunohistochemistry and CISH. This also emphasizes the need for rigorous quality control procedures for specimen preparation and analysis. © 2019 Zerbinis Publications. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback